NeurologyOnline.net

Neurology Xagena

Caffeine consumption was associated with a reduced accrual of motor and non-motor disability


Higher Caffeine consumption has been associated with reduced risk of Parkinson's disease, and with a more benign progression of motor and non-motor symptoms.
An observational cohort study investigated motor and non-motor correlates of Caffeine consumption in de novo Parkinson's disease.

79 newly diagnosed, drug naïve patients with Parkinson's disease have been included and followed up for 4 years. The total Caffeine use was calculated with the Caffeine Consumption Questionnaire. Following study variables were recorded at baseline, and after 2 and 4 years: UPDRS part III, UPDRS part IV, l-Dopa Equivalent Daily Dose ( LEDD ), NMS ( Non-Motor Symptoms ) Questionnaire [ NMSQuest ], and the time occurring from diagnosis of Parkinson's disease to the need for l-Dopa treatment.
Age, gender and disease duration were included as covariates in the statistical models.

The average daily Caffeine consumption was 296.1 ± 157.2 mg.

At Cox regression models, higher Caffeine consumption was associated with a lower rate of starting l-Dopa treatment ( hazard ratio, HR = 0.630; 95% CI = 0.382-0.996 ).

At the mixed-effects linear regression models considering the whole study period, each additional espresso cup per day ( 50 mg of Caffeine ) was more likely associated with 5-point lower UPDRS part III total score ( Coef = -0.01; 95% CI = -0.02 to 0.00 ), with 50% reduced LEDD ( Coef = -0.01; 95% CI = -0.15 to 0.00; p = 0.021 ), and with 5-point lower NMSQuest total score ( Coef = -0.01; 95% CI = -0.01 to 0.00 ), but not with UPDRS part IV total score ( Coef = -0.00; 95% CI = -0.00 to 0.00 ).

In conclusion, Caffeine consumption was associated with a reduced accrual of motor and non-motor disability during 4-year follow-up in de novo Parkinson's disease, highlighting the rationale for using adenosine A2A antagonists since the early phases of Parkinson's disease. ( Xagena )

Moccia M et al, Parkinsonism Relat Disord 2016; 32: 116-119

XagenaMedicine_2016



Indietro